Advertisement

The R&D Market Pulse Index for the week ending August 11, 2017 closed at 3,405.57 for the 25 companies in the R&D Index. The Index was down -1.52% (or 52.41 basis points) over the week ending August 4, 2017. Three R&D Index companies gained value last week from 0.19% (Qualcomm) to 1.39% (Bristol-Myers Squibb). Twenty-two R&D Index companies lost value last week from -0.06% (Johnson & Johnson) to -4.29% (GlaxoSmithKline).

The increasingly acrimonious dialogue last week between President Trump and North Korea was the primary reason for the declines seen in the R&D Index members, along with most all global stock indices. The declines continued most of last week, with only a token gain on Friday. The CBOE (Chicago Board Options Exchange) Volatility Index (referred to as the 'fear index') rose to its highest level (16.04) since last November, which had fallen to a record low in recent weeks reflecting a calm period.

The Dept. of Labor reported last week that the U.S. inflation rate is running at about a 1.7% increase over 2016, below the Fed's desired rate of 2.0%. Consumer prices rose only 0.1% in July. These low rates puzzle Federal Reserve officials, who expect them to be higher for the U.S. economy's considerable growth over the past year. July saw some gains in airfares, apparel, physicians' services and prescription drug prices, which could imply a further inflationary increase in the coming months, according to analysts. The low inflation rate may cause the Fed to reconsider or delay its plans for another short-term interest rate hike this Fall.

R&D Index member Apple's R&D spending for its third quarter, which ended July 1, rose 15% over its Q3 2016 R&D spending to $2.9 billion. Its 12-month R&D was $11.2 billion which is about 5% of its revenue for the period, a level of R&D it has not invested in since 2004. Apple is close-mouthed about its R&D investments. Analysts expect much of it is being spent on self-driving cars, health-care monitoring or augmented reality—along with its next generation of iPhones and cellular-enabled smart-watches. It should be noted that Apple's current R&D spending still trails its big tech competitors—Amazon, Google and Microsoft—by 30% to 60%.

A report by the OECD last week noted that most of the largest economies are expected to see increases in Q2 2017 with global growth increasing to 3.7% in Q2 from 3.2% in Q1. The UK and Russia are expected to see slower growth and the U.S. is expected to see stable growth. The slower U.S. growth forecast for Q2 was due to the lack of any increases in investment spending (R&D) and tax cuts that were expected, but did not happen.

      R&D Index Week Ending August 11, 2017      
    Ticker Exchange 2017 R&D billions$ 08/04/17 08/11/17 8/11/17 to 8/4/17 8/11/17 to 1/1/17
1 Amazon AMZN NASDAQ 17,774 987.58 967.99 -1.98% 29.09%
2 Alphabet/Google GOOGL NASDAQ 15,845 945.79 930.09 -1.66% 17.37%
3 Microsoft MSFT NASDAQ 13,987 72.68 72.50 -0.25% 16.67%
4 Intel INTC NASDAQ 13,499 36.30 35.87 -1.18% -1.10%
5 Apple AAPL NASDAQ 11,506 156.39 157.48 0.70% 35.97%
6 Volkswagen AG VLKAY OTC 11,260 31.04 30.40 -2.06% 6.00%
7 Roche Pharm RHHBY OTC 10,174 31.92 31.48 -1.38% 10.34%
8 Toyota TM NYSE 9,170 113.64 112.12 -1.34% -4.33%
9 Johnson & Johnson JNJ NYSE 9,060 133.18 133.10 -0.06% 15.53%
10 Novartis NVS NYSE 7,870 84.97 83.35 -1.91% 14.43%
11 General Motors GM NYSE 7,468 35.27 34.93 -0.96% -0.26%
12 Pfizer PFE NYSE 7,288 33.64 33.25 -1.16% 2.37%
13 Bristol-Myers Squibb BMY NYSE 6,942 55.95 56.73 1.39% -2.93%
14 Cisco CSCO NASDAQ 6,827 31.80 31.47 -1.04% 4.14%
15 Qualcomm QCOM NASDAQ 6,723 52.62 52.72 0.19% -19.14%
16 Oracle ORCL NYSE 6,702 49.96 48.24 -3.44% 25.46%
17 Honda HMC NYSE 6,519 28.37 27.56 -2.86% -5.58%
18 Astra Zeneca PLC AZN NYSE 6,363 30.17 29.08 -3.61% 6.44%
19 Merck & Co. MRK NYSE 5,759 63.10 62.38 -1.14% 5.96%
20 Daimler DDAIY OTC 5,084 60.53 59.80 -1.21% -15.44%
21 Bayer AG BAYN XETRA 4,880 107.00 105.70 -1.22% 6.63%
22 Sanofi SA SNY NYSE 4,755 48.08 47.55 -1.10% 17.58%
23 IBM IBM NYSE 4,628 145.16 141.84 -2.29% -14.55%
24 GlaxoSmithKline GSK NYSE 4,508 40.53 38.79 -4.29% 0.73%
25 Eli Lilly Co LLY NYSE 4,489 82.31 81.15 -1.41% 10.33%
  Total     209,080 3,457.98 3,405.57 -1.52% 14.19%
                 
      Biopharmaceutical 710.85 702.56 -1.17% 8.87%
      Automotive 268.85 264.81 -1.50% -5.64%
      ICT   1,490.70 1,470.21 -1.37% 12.53%

About the R&D Index

The R&D Market Pulse Index is a weekly stock market summary of the top international companies involved in research and development. The top 25 industrial spenders of R&D in 2017 were selected based on the latest listings from Schonfeld & Associates' June 2017 R&D Ratios & Budgets. These 25 companies include pharmaceutical (11 companies), automotive (5), ICT  (8) and conglomerate (1) organizations who invested a cumulative total of more than $209 billion in R&D in 2017, or approximately 10% of all the R&D spent in the world by government, industries and academia combined, according to R&D Magazine's 2017 Global R&D Funding Forecast. The stock prices used in the R&D Index are tabulated from NASDAQ, NYSE, XETRA and OTC common stock prices (in U.S. dollars) for the companies selected at the close of stock trading business on the Friday preceding the publication of the R&D Market Pulse Index in R&D Magazine's R&D Daily eNewsletter.

The companies used in the R&D Index include Amazon, Alphabet/Google, Microsoft, Intel, Apple, Volkswagen AG, Roche Pharma, Toyota, Johnson & Johnson, Novartis, General Motors, Pfizer, Bristol-Myers Squibb, Cisco, Qualcomm, Oracle, Honda Motor Company, Astra Zeneca plc, Merck & Company, Daimler, Bayer AG, Sanofi SA, IBM, GlaxoSmithKline and Eli Lilly Co. Stock prices are based on those stocks traded on the U.S. exchanges. R&D Index trends (in the stock prices) are just one indicator of the amount of capital available to these high-technology companies to invest in R&D and should not be implied to indicate the absolute value of R&D investments made by these organizations. The companies chosen for the R&D Index have very large sophisticated internal and global R&D organizations with each company investing between $4.5 and $17 billion annually on their R&D efforts.

 

Advertisement
Advertisement